Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
musculoskeletal diseases | D009140 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TURALIO | Daiichi Pharmaceutical | N-211810 RX | 2022-10-14 | 1 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
turalio | New Drug Application | 2025-01-16 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
giant cell tumor of tendon sheath | — | D000070779 | — |
Expiration | Code | ||
---|---|---|---|
PEXIDARTINIB HYDROCHLORIDE, TURALIO, DAIICHI SANKYO INC | |||
2026-08-02 | ODE*, ODE-250 | ||
2024-08-02 | NCE |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Pexidartinib Hydrochloride, Turalio, Daiichi Sankyo Inc | |||
10435404 | 2038-07-24 | DP | |
10941142 | 2038-07-24 | DP | |
10961240 | 2038-07-24 | U-2606 | |
9802932 | 2036-05-05 | DP | |
10189833 | 2036-05-05 | U-2606 | |
10730876 | 2036-05-05 | DP | |
9358235 | 2033-06-08 | U-2606 | |
7893075 | 2033-05-04 | DP | |
8461169 | 2028-04-19 | U-2606 | |
8404700 | 2027-11-21 | DP | |
8722702 | 2027-11-21 | DP | |
9169250 | 2027-11-21 | DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Giant cell tumors | D005870 | — | — | — | 1 | 2 | 1 | 1 | 5 |
Giant cell tumor of tendon sheath | D000070779 | — | — | — | 1 | 2 | 1 | 1 | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 3 | — | 1 | — | — | 4 |
Synovitis | D013585 | EFO_0008997 | M67.5 | — | — | 1 | — | — | 1 |
Pigmented villonodular synovitis | D013586 | EFO_1001106 | M12.2 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Melanoma | D008545 | — | — | 2 | 1 | — | — | 1 | 3 |
Glioblastoma | D005909 | EFO_0000515 | — | 1 | 2 | — | — | — | 2 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 1 | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | 1 | 1 | — | — | — | 1 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | 1 | — | — | — | 1 |
Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | 1 | 1 | — | — | — | 1 |
Sarcoma | D012509 | — | — | 1 | 1 | — | — | — | 1 |
Neurofibrosarcoma | D018319 | — | — | 1 | 1 | — | — | — | 1 |
Nerve sheath neoplasms | D018317 | EFO_0000760 | — | 1 | 1 | — | — | — | 1 |
Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Pexidartinib |
INN | pexidartinib |
Description | Pexidartinib is a pyrrolopyridine that is 5-chloro-1H-pyrrolo[2,3-b]pyridine which is substituted by a [6-({[6-(trifluoromethyl)pyridin-3-yl]methyl}amino)pyridin-3-yl]methyl group at position 3. It is a potent multi-targeted receptor tyrosine kinase inhibitor of CSF-1R, KIT, and FLT3 (IC50 of 20 nM, 10 nM and 160 nM, respectively). Approved by the FDA for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT). It has a role as an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor and an antineoplastic agent. It is a pyrrolopyridine, an organochlorine compound, an aminopyridine, an organofluorine compound and a secondary amino compound. |
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1 |
PDB | — |
CAS-ID | 1029044-16-3 |
RxCUI | — |
ChEMBL ID | CHEMBL3813873 |
ChEBI ID | — |
PubChem CID | 25151352 |
DrugBank | DB12978 |
UNII ID | 6783M2LV5X (ChemIDplus, GSRS) |